NASDAQ$VRCA
Verrica Pharmaceuticals Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Verrica's Q2 2023 financial results were announced, featuring FDA approval of YCANTH™ and a secured $125 million debt facility.
Verrica Pharmaceuticals reported its Q2 2023 financial results, highlighted by the FDA approval of YCANTH™ for molluscum treatment and a $125 million debt facility to support its launch. The company's cash runway has been extended into the first quarter of 2025.
- FDA approved YCANTH™ for treating molluscum.
- YCANTH™ launch is expected by September 2023.
- Expanded Part 2 enrollment of VP-315 Phase 2 trial in basal cell carcinoma to accelerate clinical development.
- Secured a $125 million debt facility to support the launch of YCANTH™.
Headline financials
Revenue & EPS history
Verrica · Revenue · Quarterly
$182K
Forward guidance
The company expects to commercially launch YCANTH™, achieve revenue milestones under the debt facility, and fund operations into Q1 2025.
Tailwinds
- Successful commercial launch of YCANTH™.
- Achievement of revenue milestones under the debt facility.
- Availability of future financing from the debt facility with OrbiMed.
- Ability to fund ongoing operations without additional equity financing if the additional $75 million is borrowed.
- Ability to fund its operations into the first quarter of 2025.
Headwinds
- Uncertainties inherent in the drug development process.
- Uncertainties inherent in the regulatory approval process.
- Reliance on third parties over which it may not always have full control.
- Uncertainties described in Verrica’s Annual Report on Form 10-K.
- Risks that could cause actual results to differ materially from expectations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
-2.7%
Avg return
Earnings day
-3.4%
Avg return
5 days after
-1.1%
Avg return
30 days after
42%
13 / 31 earnings
Positive
+18.6%
Q1 2024
Best reaction
-47.9%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.8% | -15.3% | -19.9% | |
| Q4 2025 | +4.7% | +3.2% | -14.5% | |
| Q3 2025 | +3.2% | +15.8% | +104.7% | |
| Q1 2025 | +2.9% | -0.8% | -3.0% | |
| Q4 2024 | -7.6% | +0.5% | -25.3% | |
| Q3 2024 | -47.9% | -45.8% | -22.2% | |
| Q2 2024 | -44.8% | -43.8% | -62.6% | |
| Q1 2024 | +18.6% | +8.4% | +7.3% | |
| Q4 2023 | -3.0% | -10.1% | +3.5% | |
| Q3 2023 | -13.6% | -17.7% | +7.6% | |
| Q2 2023 | +7.6% | +1.6% | -18.5% | |
| Q1 2023 | -1.4% | -7.1% | -13.9% | |
| Q4 2022 | -6.9% | +1.5% | -21.6% | |
| Q3 2022 | -3.1% | +3.1% | +43.7% | |
| Q2 2022 | +17.1% | +9.6% | +18.8% | |
| Q1 2022 | -1.6% | -7.8% | -63.0% | |
| Q4 2021 | +1.3% | -7.7% | +1.9% | |
| Q3 2021 | -4.2% | -5.9% | -22.2% | |
| Q2 2021 | -1.6% | -0.7% | +12.6% | |
| Q1 2021 | -0.8% | -0.2% | -14.8% | |
| Q4 2020 | -9.6% | -0.2% | +1.3% | |
| Q3 2020 | +13.9% | +13.1% | +32.3% | |
| Q2 2020 | +5.6% | +4.8% | +29.6% | |
| Q1 2020 | +10.5% | +2.8% | +24.0% | |
| Q4 2019 | -12.1% | -7.5% | +31.3% | |
| Q3 2019 | +0.8% | +4.0% | -7.3% | |
| Q2 2019 | +2.6% | -9.3% | -2.3% | |
| Q1 2019 | +1.0% | -3.3% | -23.4% | |
| Q4 2018 | -7.5% | +1.1% | -8.0% | |
| Q3 2018 | -3.8% | +5.6% | -22.7% | |
| Q2 2018 | -0.9% | +2.7% | +13.8% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro